Seiichiro Kamimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seiichiro Kamimura has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Yoshiaki Kitamura
Department of Otolaryngology, Graduate School of Medicine, Tokushima University, Tokushima, Japan
8 shared publications Eiji Kondo
3 shared publications- Go Sato
Department of Otolaryngology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
3 shared publications Noriaki Takeda
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan
3 shared publications- Noriaki Takeda
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
3 shared publications - Takahiro Azuma
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan
3 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 39
Ultrasound-guided closed reduction of nasal bone fracture using a superabsorbent polymer ice gel pack: A case study
- 17 March 2026
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 39
Open AccessUltrasound-guided closed reduction of nasal bone fracture using a superabsorbent polymer ice gel pack: A case study
- 3 March 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 309-323
Vestibular assessment in definite cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): A case of siblings study
- 3 March 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 309-323
Vestibular assessment in definite cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): A case of siblings study
- Open Access
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
Open AccessHigh Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- Open Access
- 5 January 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101555
Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
- 5 January 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101555
Open AccessEffect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
- Open Access
- 11 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e69171
SWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily B Member 1 (SMARCB1)-Deficient Tumor in the Parapharyngeal Space: A Case Report
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) is a tumor suppressor gene, and SMARCB1 deficits have been associated with numerous malignant tumors. Carcinomas with a SMARCB1 deficit generally have a poor prognosis. In the head and neck region, there have been many recent cases of SMARCB1-deficient sinonasal carcinoma, but reports of extrasinonasal sites are extremely rare. This study reports a case of SMARCB1-deficient tumor in the right parapharyngeal space. A 64-year-old woman with right neck swelling was presented to our hospital, and imaging revealed a tumor in the right parapharyngeal space. After four years of follow-up, the tumor had increased in size, and a biopsy revealed deficits in SMARCB1 in the tumor cells. No definitive histological diagnoses were made. Radiation reduced the size of the tumor, and the patient survived without progression, three years after completion of treatment.
- 11 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e69171
Open AccessSWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily B Member 1 (SMARCB1)-Deficient Tumor in the Parapharyngeal Space: A Case Report
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) is a tumor suppressor gene, and SMARCB1 deficits have been associated with numerous malignant tumors. Carcinomas with a SMARCB1 deficit generally have a poor prognosis. In the head and neck region, there have been many recent cases of SMARCB1-deficient sinonasal carcinoma, but reports of extrasinonasal sites are extremely rare. This study reports a case of SMARCB1-deficient tumor in the right parapharyngeal space. A 64-year-old woman with right neck swelling was presented to our hospital, and imaging revealed a tumor in the right parapharyngeal space. After four years of follow-up, the tumor had increased in size, and a biopsy revealed deficits in SMARCB1 in the tumor cells. No definitive histological diagnoses were made. Radiation reduced the size of the tumor, and the patient survived without progression, three years after completion of treatment.
- Open Access
- 21 January 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (1) , 36-42
Efficacy of dual sublingual immunotherapy with Japanese cedar pollen and house dust mite allergens in patients with allergic rhinitis sensitized to multiple allergens
Objective: In the present study, we examined the effects of dual sublingual immunotherapy (SLIT) with Japanese cedar pollen (JCP) and house dust mite (HDM) allergens on nasal symptoms during the peak pollen period (PPP) and in late fall (LF) in patients with allergic rhinitis (AR) sensitized to both JCP and HDM. We then compared the efficacy of dual‐SLIT with JCP and HDM to that of mono‐SLIT with JCP at PPP.Methods: Twenty‐five bisensitized patients with AR who showed positive serum specific immunoglobulin E (IgE) against both JCP and HDM were enrolled. In dual‐SLIT, 16 patients received JCP drops/tablets and HDM tablets concurrently. In mono‐SLIT with JCP, nine patients received JCP drops/tablets. Nasal symptoms were scored on a 0–4 point scale.Results: The nasal scores at PPP and in LF in the bisensitized patients with AR who received dual‐SLIT with JCP and HDM in 2019 were significantly lower than those in the same patients who received antihistamines only in 2018. The decrease in scores of nasal obstruction at PPP from 2018 to 2019 in patients who received dual‐SLIT was significantly greater than those in patients who received mono‐SLIT with JCP. Dual‐SLIT was well tolerated and only had mild adverse effects.Conclusion: These findings suggest that dual‐SLIT suppressed both JCP‐induced seasonal and HDM‐induced perennial nasal symptoms in bisensitized patients with AR. Dual‐SLIT was more effective in suppressing nasal obstruction at PPP than mono‐SLIT with JCP with limitation of baseline characteristics not to be controlled between the two groups, suggesting that dual‐SLIT suppressed HDM‐induced priming effects, thus resulting in further suppression of nasal obstruction at PPP.Level of Evidence: 3b, a case‐controlled study
- 21 January 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (1) , 36-42
Open AccessEfficacy of dual sublingual immunotherapy with Japanese cedar pollen and house dust mite allergens in patients with allergic rhinitis sensitized to multiple allergens
Objective: In the present study, we examined the effects of dual sublingual immunotherapy (SLIT) with Japanese cedar pollen (JCP) and house dust mite (HDM) allergens on nasal symptoms during the peak pollen period (PPP) and in late fall (LF) in patients with allergic rhinitis (AR) sensitized to both JCP and HDM. We then compared the efficacy of dual‐SLIT with JCP and HDM to that of mono‐SLIT with JCP at PPP.Methods: Twenty‐five bisensitized patients with AR who showed positive serum specific immunoglobulin E (IgE) against both JCP and HDM were enrolled. In dual‐SLIT, 16 patients received JCP drops/tablets and HDM tablets concurrently. In mono‐SLIT with JCP, nine patients received JCP drops/tablets. Nasal symptoms were scored on a 0–4 point scale.Results: The nasal scores at PPP and in LF in the bisensitized patients with AR who received dual‐SLIT with JCP and HDM in 2019 were significantly lower than those in the same patients who received antihistamines only in 2018. The decrease in scores of nasal obstruction at PPP from 2018 to 2019 in patients who received dual‐SLIT was significantly greater than those in patients who received mono‐SLIT with JCP. Dual‐SLIT was well tolerated and only had mild adverse effects.Conclusion: These findings suggest that dual‐SLIT suppressed both JCP‐induced seasonal and HDM‐induced perennial nasal symptoms in bisensitized patients with AR. Dual‐SLIT was more effective in suppressing nasal obstruction at PPP than mono‐SLIT with JCP with limitation of baseline characteristics not to be controlled between the two groups, suggesting that dual‐SLIT suppressed HDM‐induced priming effects, thus resulting in further suppression of nasal obstruction at PPP.Level of Evidence: 3b, a case‐controlled study
- 4 January 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (4) , 697-702
Long-term changes in serum squamous cell carcinoma antigen levels after surgery in patients with sinonasal inverted papilloma
- 4 January 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (4) , 697-702
Long-term changes in serum squamous cell carcinoma antigen levels after surgery in patients with sinonasal inverted papilloma
- Open Access
Effects of Syo-seiryu-to and Its Constituent Crude Drugs on Phorbol Ester-Induced Up-Regulation of IL-33 and Histamine H1 Receptor mRNAs in Swiss 3T3 and HeLa Cells
Syo-seiryu-to (SST) is a traditional herbal medicine that has been used clinically to treat allergic rhinitis (AR) in Japan. SST improves acute symptoms, such as sneezing and rhinorrhea, as well as chronic symptoms, such as nasal obstruction, in patients with AR. However, its therapeutic mechanisms remain unknown. We examined the effects of SST and eight constituent crude drugs on phorbol 12-myristate-13-acetate (PMA)-induced gene up-regulation of IL-33 and histamine H1 receptor (H1R), which are responsible for the pathogenesis of AR. We found that SST and its crude drugs, except for Pinellia tuber, significantly and dose-dependently suppressed PMA-induced both IL-33 and H1R mRNA up-regulation in vitro. The half-maximal inhibitory concentration values of the seven crude drugs to inhibit PMA-induced IL-33 mRNA up-regulation were correlated with those related to H1R mRNA up-regulation, suggesting that they act on a common signal molecule. These results suggest that SST improves nasal congestion that is induced by IL-33-related eosinophil infiltration and inhibits sneezing and rhinorrhea that are induced by H1R-mediated histamine signaling in the nasal mucosa of AR patients through its inhibition of a common molecule in the gene expression pathways of IL-33 and H1R. The results could explain the advantages of traditional herbal medicine, in which mixing various crude drugs not only acts on a common target to enhance its pharmacological action, similar to the effect of a high concentration of a single crude extract but also has the benefit of reducing the side effects of each crude drug.
Open AccessEffects of Syo-seiryu-to and Its Constituent Crude Drugs on Phorbol Ester-Induced Up-Regulation of IL-33 and Histamine H1 Receptor mRNAs in Swiss 3T3 and HeLa Cells
Syo-seiryu-to (SST) is a traditional herbal medicine that has been used clinically to treat allergic rhinitis (AR) in Japan. SST improves acute symptoms, such as sneezing and rhinorrhea, as well as chronic symptoms, such as nasal obstruction, in patients with AR. However, its therapeutic mechanisms remain unknown. We examined the effects of SST and eight constituent crude drugs on phorbol 12-myristate-13-acetate (PMA)-induced gene up-regulation of IL-33 and histamine H1 receptor (H1R), which are responsible for the pathogenesis of AR. We found that SST and its crude drugs, except for Pinellia tuber, significantly and dose-dependently suppressed PMA-induced both IL-33 and H1R mRNA up-regulation in vitro. The half-maximal inhibitory concentration values of the seven crude drugs to inhibit PMA-induced IL-33 mRNA up-regulation were correlated with those related to H1R mRNA up-regulation, suggesting that they act on a common signal molecule. These results suggest that SST improves nasal congestion that is induced by IL-33-related eosinophil infiltration and inhibits sneezing and rhinorrhea that are induced by H1R-mediated histamine signaling in the nasal mucosa of AR patients through its inhibition of a common molecule in the gene expression pathways of IL-33 and H1R. The results could explain the advantages of traditional herbal medicine, in which mixing various crude drugs not only acts on a common target to enhance its pharmacological action, similar to the effect of a high concentration of a single crude extract but also has the benefit of reducing the side effects of each crude drug.